Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05287113 · ClinicalTrials.gov registry record · Phase 2

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase 2 study of Head and Neck Cancer, sponsored by Incyte Biosciences International Sàrl.

Active
Registry status
Phase 2
Development phase
176
Enrollment target
20
Study locations

NCT05287113 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Incyte Biosciences International Sàrl. The registered enrollment target is 176 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05287113, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Incyte Biosciences International Sàrl.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
176 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG Placebo
  • DRUG Retifanlimab
  • DRUG INCAGN02385
  • DRUG INCAGN02390

Study Locations (20)

California

  • City of Hope National Medical Center - Duarte
  • City of Hope Orange County - Irvine
  • University of California San Diego Medical Center, Moores Cancer Center - La Jolla
  • City of Hope-Antelope Valley - Lancaster
  • Innovative Clinical Research Institute - Long Beach
  • City of Hope National Medical Center - Long Beach
  • University of California San Francisco Comprehensive Cancer Center - San Francisco

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Blessed Health Care - Miami
  • Moffitt Cancer Center - Tampa

Michigan

  • University of Michigan Cancer Center - Ann Arbor
  • Barbara Ann Karmanos Cancer Hospital - Detroit

Arizona

  • Mayo Clinic Rochester - Scottsdale

District of Columbia

  • Georgetown University - Washington D.C.

Illinois

  • University of Illinois At Chicago - Chicago

Iowa

  • University of Iowa - Iowa City

Kansas

  • University of Kansas Hospital Authority - Kansas City

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2022-11-14
Est. Completion 2026-07-10
Phase Phase 2

Sponsor

Incyte Biosciences International Sàrl

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05287113

The ClinicalTrials.gov registry entry for NCT05287113 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (32% lower). The listed sponsor is Incyte Biosciences International Sàrl, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT05287113 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT05287113 about?

NCT05287113 is a clinical study titled "Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squa...

What is the current status of trial NCT05287113?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2022-11-14. Estimated completion is 2026-07-10.

What conditions does trial NCT05287113 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT05287113?

The interventions under investigation include: Placebo (DRUG), Retifanlimab (DRUG), INCAGN02385 (DRUG), INCAGN02390 (DRUG).

Who is sponsoring clinical trial NCT05287113?

This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05287113 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.